Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

386

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Diabetes Mellitus
Interventions
DRUG

SYR-472

SYR-472 3.125 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.

DRUG

SYR-472

SYR-472 12.5 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.

DRUG

SYR-472

SYR-472 50 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.

DRUG

SYR-472

SYR-472 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.

DRUG

Placebo

SYR-472 placebo-matching tablets, orally, once daily with lifestyle modification and/or metformin therapy for up to 12 weeks.

DRUG

Sitagliptin

Sitagliptin 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.

Trial Locations (112)

Unknown

Birmingham

Mobile

Montgomery

Phoenix

Tempe

Tucson

Anderson

Little Rock

Pine Bluff

Carmichael

Chino

Long Beach

Los Angeles

Los Gatos

Orange

Pico Rivera

Rolling Hills Estates

Roseville

Rowland Heights

Sacramento

Santa Ana

Stockton

Torrance

Arvada

Colorado Springs

Highlands Ranch

Avon

Rocky Hill

Newark

Aventura

Edgewater

Hollywood

Jacksonville

Kissimmee

Merritt Island

Miami

New Port Richey

Ocala

Pembroke Pines

Tampa

Zanesville

Atlanta

Roswell

Waycross

Idaho Falls

Chicago

Avon

Fort Wayne

Des Moines

Waterloo

Topeka

Wichita

Crestview

Oxon Hill

Detroit

Troy

Olive Branch

Kansas City

St Louis

Omaha

Las Vegas

West Caldwell

Wildwood Crest

Albuquerque

East Islip

Lewiston

New York

North Massapequa

Wantagh

Hickory

Statesville

Tabor City

Bismarck

Cincinnati

Columbus

Mason

Wadsworth

Norman

Oklahoma City

Tulsa

Eugene

Medford

Bensalem

Connellsville

Philadelphia

Pittsburgh

Shippensburg

Charleston

Greer

North Myrtle Beach

Chattanooga

Memphis

New Tazewell

Carrolton

Dallas

Georgetown

Houston

Killeen

San Antonio

Salt Lake City

Spanish Fork

Richmond

Suffolk

Virginia Beach

Spokane

Zapopan

Monterrey

Puebla City

Mexico City

Monterrey

Nezahualcóyotl

Veracruz

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT00760344 - Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter